To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
16 Current news from the ressort price development
rss
BASF increases prices for vitamin B2
07-09-2012
BASF globally increases the price for vitamin B2-products for human and animal nutrition by 10% with immediate effect respectively according to existing contracts terms at the earliest possible date.
Evonik increases prices of cGMP-grade amino acids
26-04-2012
Effective immediately, Evonik Industries is increasing the prices for the products L-Ornithine-L-Aspartate, L-Proline, L-Lysine salts, L-Methionine, L-Arginine-L-Aspartate, Glycine and all other cGMP-grade amino acids. The increase amounts to 10 – 20 percents and applies globally to all new ...
BASF increases prices for pharmaceutical excipients and active ingredients
31-08-2011
Effective September 1, 2011, BASF will increase the sales prices globally for all pharmaceutical excipients and generic active pharmaceutical ingredients by 10%. This price increase affects the entire excipients portfolio including all binders, disintegrants, coatings, solubilizers, and ...
Medivir Announces Positive 48-week Interim Data from TMC435 Hepatitis C Phase 2b ASPIRE Study in Treatment-Experienced Genotype-1 Patients
24-05-2011
Medivir AB announced results from the ASPIRE phase 2b study that evaluates the addition of once daily TMC435 to pegylated interferon and ribavirin in patients with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon (PegIFN) and ribavirin (RBV) was unsuccessful ...
Evonik increases prices of pharmaceutical amino acids
11-05-2011
Effective immediately, Evonik Industries is increasing the prices of its pharmaceutical amino acids. The increase, of between 10 and 15 percent depending on the amino acid and its quality, applies globally to all new orders and new supply agreements. The price increase is a result of the ...
BASF increases prices for pharmaceutical excipients and active ingredients
05-04-2011
Effective April 1, 2011, BASF will increase the sales prices globally for all pharmaceutical excipients and active pharmaceuticals ingredients by at least 10% ...
BASF Increases Prices for Nature-Identical Carotenoids for Human and Animal Nutrition, Excluding Astaxanthin
04-04-2011
BASF globally increases prices for all nature-identical carotinoid formulations containing canthaxanthin, citranaxanthin, C30-ester and beta-carotene ...
Price increases for functional polymers for pharmaceutical applications
12-11-2010
The Pharma Polymers business line, part of Evonik Röhm GmbH, a subsidiary of Evonik Industries AG, will implement price increases for its methyl methacrylate-based polymers for pharmaceutical applications by up to 12% for their global EUDRAGIT® business, effective January 1, 2011. The ...
Novartis drug Tasigna recommended for approval in European Union for newly diagnosed Ph+ chronic myeloid leukemia
28-09-2010
Novartis has received a positive opinion recommending European Union approval of Tasigna® (nilotinib), a selective targeted therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The Committee for Medicinal ...
Positive Study Findings from Lixisenatide in First Phase III GetGoal Trial for Type 2 Diabetes
22-09-2010
Zealand Pharma A/S announced that the positive study findings from the first Phase III GetGoal clinical trial program with lixisenatide will be presented by Zealand Pharma's partner, sanofi-aventis, at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, ...
Netmeeting
